ACTICOR BIOTECH EO 1
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Market Cap & Net Worth: ACTICOR BIOTECH EO 1 (7V7)
ACTICOR BIOTECH EO 1 (F:7V7) has a market capitalization of $11.88 Million (€11.57 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #30379 globally and #3356 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACTICOR BIOTECH EO 1's stock price €0.75 by its total outstanding shares 15510100 (15.51 Million).
ACTICOR BIOTECH EO 1 Market Cap History: 2021 to 2024
ACTICOR BIOTECH EO 1's market capitalization history from 2021 to 2024. Data shows change from $72.44 Million to $11.88 Million (-50.84% CAGR).
ACTICOR BIOTECH EO 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACTICOR BIOTECH EO 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 7V7 by Market Capitalization
Companies near ACTICOR BIOTECH EO 1 in the global market cap rankings as of March 19, 2026.
Key companies related to ACTICOR BIOTECH EO 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ACTICOR BIOTECH EO 1 Historical Marketcap From 2021 to 2024
Between 2021 and today, ACTICOR BIOTECH EO 1's market cap moved from $72.44 Million to $ 11.88 Million, with a yearly change of -50.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €11.88 Million | -78.56% |
| 2023 | €55.40 Million | -48.82% |
| 2022 | €108.26 Million | +49.45% |
| 2021 | €72.44 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 27th, 2025 the market cap of ACTICOR BIOTECH EO 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.88 Million USD |
| MoneyControl | $11.88 Million USD |
| MarketWatch | $11.88 Million USD |
| marketcap.company | $11.88 Million USD |
| Reuters | $11.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.